Birociclib is a Class 1 innovative drug (CDK 4/6 inhibitor) independently developed by XZeinth, which has been applied for NDA and has been accepted. Indications under development include combination fulvestrant therapy, combination Al drug therapy, and Birociclib monotherapy.

KM-501 (bispecific antibody-drug conjugates) is a HER 2 bi-epitope bispecific ADC independently developed by Combio, which was developed by using antibody editing (Mab-Edit), endocytic optimization and non-fixed / fixed-point coupling techniques.

XZP-3621 is independently developed by XZenith, an ALK inhibitor drug for NSCLC, which has better safety and efficacy. lt is currently in Phase III clinical stage.

XZB-0004 is a oral small molecule AXL kinase inhibitor with high selectivity, high efficiency and very low side effects, which can enhance the efficacy of existing therapies and address incurable unmet clinical needs. It is currently in the clinical research stage.